Literature DB >> 3383968

Orosomucoid:prealbumin ratio--a marker of the host-tumor relationship in head and neck cancer.

C Caldani1, A Thyss, M Schneider, G Milano, L Buray, F Demard.   

Abstract

The OPR was studied in 203 patients with squamous cell carcinoma of the head and neck at the time of diagnosis, before any specific treatment. The mean initial OPR value was significantly higher in cancer patients than in 63 healthy controls: 5.29 +/- 3.09 vs. 2.63 +/- 1.07; P less than 0.001. There was no significant difference by anatomic site, but the OPR was significantly lower in stage I-II disease than in stage III-IV: 5.10 +/- 3.85 vs. 3.23 +/- 1.99, P less than 0.001. An initial OPR under or over 6 seems to be an important prognostic factor: at 2 years, 51% of patients with an OPR less than 6 were alive vs. only 24.5% of those with an OPR greater than 6, P less than 0.001. The difference was also noted in patients with stage III-IV disease (mean survival: 16 months vs. 7 months, P less than 0.001) and in 89 of the patients who received chemotherapy (mean survival 16 months vs. 6 months, P less than 0.001) whatever the response to chemotherapy. The OPR index, which explores nutritional and acute phase reactant proteins, seems to reflect the host-tumor relationship. Its initial value is strongly related to prognosis at 2 years.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3383968     DOI: 10.1016/0277-5379(88)90295-7

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  2 in total

1.  Association of a alpha1 acidic glycoprotein and squamous cell carcinoma of the head and neck.

Authors:  M V Croce; M R Price; A Segal-Eiras
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

Review 2.  Targeting Cellular Metabolism Modulates Head and Neck Oncogenesis.

Authors:  Yi-Ta Hsieh; Yi-Fen Chen; Shu-Chun Lin; Kuo-Wei Chang; Wan-Chun Li
Journal:  Int J Mol Sci       Date:  2019-08-14       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.